Raymond Douglas, MD, PhD, Unveils Research on Six-Week Teprotumumab Dosing to Help Protect Hearing
LOS ANGELES, Oct. 12, 2026 – Raymond Douglas, MD, PhD, a lead scientist behind the first FDA-approved treatment…
Browsing Tag
teprotumumab;thyroid eye disease;Hearing Loss;Clinical Trial;dosing schedule;Side Effects;audiometry;autoimmune conditions
1 post